Participant flow

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma · Source last updated 2016-08-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma

   id

   FG000

   title

   Dasatinib

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         43

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         43

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Three (3) participants withdrew from the study before treatment initiation; therefore 43 participants were eligible for evaluation

recruitment Details

Between September 2007 to August 2009, 46 participants were recruited.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice